Biocept Launches Clinical Research Services for Biomarker Detection in Circulating Tumor DNA
This service will be performed at
"We are excited to launch our services for pharmaceutical research, development and clinical trials," said
The number of therapeutic biomarkers
"The next logical step in expanding our service offering to a broader audience is through the extension of our capabilities beyond referring physicians to pharmaceutical companies and academia. All of these groups stand to benefit from our ability to identify key biomarkers from simple blood samples. Our ability to capture and analyze genomic changes both in intact CTCs as well as cell-free tumor DNA will allow our pharmaceutical partners to achieve the sensitive detection of driver and drug resistance mutations," said
Some of the key programs for the clinical research offering include:
- ALK and ROS1 translocations on CTCs, with a focus on NSCLC
- MET copy number analysis on CTCs, with a focus on non-small cell lung cancer (NSCLC) and gastrointestinal (GI) cancers
- Her2 copy number analysis on CTCs, with a focus on breast cancer and GI cancer
- ER protein expression on CTCs, with a focus on breast cancer
- AR, PTEN and MYC copy number and loss of gene regions in CTCs, with a focus on prostate cancer
- EGFR mutation analysis on cell-free tumor DNA, with a focus on NSCLC
- KRAS mutation analysis on cell-free tumor DNA, with a focus on NSCLC and colon cancer
In addition to these assays,
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to anticipated product introductions and their capabilities, and anticipated expansion of our
service offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
CONTACT: Investor Contact:Source:The Ruth Group David Burke (646) 536-7009 dburke@theruthgroup.com Media Contact:The Ruth Group Melanie Sollid-Penton (646) 536-7023 msollid@theruthgroup.com
News Provided by Acquire Media